Core Insights - Aclarion, Inc. has published a peer-reviewed article demonstrating the cost-effectiveness of its Nociscan solution compared to provocative discography for identifying chronic low back pain surgery candidates [1][2] - The study indicates that Nociscan saves approximately $1,712 per patient and improves surgical success rates by 10% [5] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to help physicians differentiate between painful and non-painful discs [4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively assist in diagnosing disc-related pain [4] Industry Context - Chronic low back pain affects around 266 million people globally, highlighting the significant healthcare challenge it presents [2] - The publication in ClinicoEconomics and Outcomes Research emphasizes the need for more evidence on clinical and economic improvements in healthcare diagnostics [1]
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis